ArticleThe Australian & New Zealand journal of obstetrics & gynaecology2026
A Scoping Systematic Review of Cannabis Use in Endometriosis.
Article in The Australian & New Zealand journal of obstetrics & gynaecology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cannabis-Based Medicinal Products for Endometriosis: A 2-Year Prospective Analysis From the UK Medical Cannabis Registry.The Australian & New Zealand journal of obstetrics & gynaecology · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEndometriosis, affecting 6%-10% of reproductive-age women, causes chronic pelvic pain, dysmenorrhea, and infertility. Current treatments have limitations and consequently there is rising interest in effects of cannabis on pain and inflammation associated with endometriosis.
aimsThis scoping review primarily aimed to characterise the effects of cannabis on endometriosis-associated pain and detail the reported adverse events. MATERIALS AND
methodsA search was collected on PubMed, MEDLINE (Ovid), and EMBASE (Ovid) databases on 16th January 2024. Studies were included if they were in-human or clinical studies evaluating the effects of cannabis in endometriosis in non-pregnant adults.
resultsThirteen studies, including 4 ongoing studies, were included. All nine completed studies, with 1,787 participants, were cross-sectional. Pain (57.3%-95.5%) was the most common indication for cannabis use, followed by sleep and gastrointestinal distress (15.2%-78.5%). Cannabis was most commonly inhaled (51.6%-80.3%) or ingested (25%-76.9%). Eight (61.5%) studies asked about participants' perception of the efficacy of cannabis. These utilised a range of methods preventing pooling of results. However, most reported improvement in at least a proportion of their studied population. Adverse events were reported by 10.2% to 52.0% of patients, with the most common being "feeling high" (euphoria) and a dry mouth.
conclusionsSeveral observational studies have reported that cannabis helped to reduce endometriosis-associated pain. However, there is a paucity of high-quality prospective longitudinal data and randomised controlled trials to evaluate the safety profile an efficacy of medical cannabis in endometriosis-associated pain. These provide support, alongside existing pre-clinical data, for the importance of further assessment in randomised controlled trials.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.